Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1996 Dec;106(3):468–474. doi: 10.1046/j.1365-2249.1996.d01-870.x

Contribution of tumour necrosis factor-alpha (TNF-α) in host defence mechanism against Cryptococcus neoformans

K KAWAKAMI 1, X QIFENG 1, M TOHYAMA 1, M H QURESHI 1, A SAITO 1
PMCID: PMC2200622  PMID: 8973614

Abstract

We investigated the role of TNF-α in the host defence mechanism against infection with a virulent strain of Cryptococcus neoformans. Administration of exogenous recombinant human TNF-α significantly prolonged the survival time of mice infected by intratracheal instillation of the organism. Surprisingly, neutralizing MoAb to murine TNF-α did not shorten their survival time, a finding inconsistent with previous results. To investigate the cause of this inconsistency, we examined the production of TNF-α in the lungs of infected mice. During the course of cryptococcosis, there was little or no generation of TNF-α mRNA in the lung. This might be partly due to a direct inhibitory action of the fungal microorganism on TNF-α production by macrophages. In vitro production of TNF-α by murine interferon-gamma (IFN-γ)- and lipopolysaccharide (LPS)-stimulated macrophages was strongly inhibited by co-culturing with the whole yeast cells. In contrast, administration of recombinant murine IL-12 markedly induced TNF-α production and the neutralizing anti-TNF-α MoAb strongly blocked IL-12-induced protection of mice against cryptococcal infection. These results indicate that endogenously synthesized TNF-α has the potential to contribute to the elimination of C. neoformans and partly mediates the protective effect of IL-12.

Keywords: Cryptococcus neoformans, macrophages, IL-12, tumour necrosis factor-alpha

Full Text

The Full Text of this article is available as a PDF (368.4 KB).


Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES